Tissue-Resident NK Cells Slow Solid Tumor Growth in Mice
June 16, 2026
The study points to a possible off-the-shelf cell therapy for solid tumors
2 min read
False
Advertisement
Research News
Stem Cells More Cost-Effective than Gene Therapy for Sickle Cell Disease
June 16, 2026
Researchers found gene therapy produced the highest modeled health benefit, but haploidentical stem cell transplantation offered better value at current prices
2 min read
This Week’s Biopharma News: Big Moves in Bispecifics
June 9, 2026
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
4 min read
This Week’s CGT News: Promising Data for In Vivo CAR T
June 8, 2026
Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts
5 min read
This Week’s Biopharma News: New Approvals, Appeals, and AI
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
This Week’s CGT News: Base Editing Takes Aim at Cholesterol
June 1, 2026
Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M
3 min read
This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves
May 26, 2026
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
7 min read
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
This Week’s CGT News: Novo’s Parkinson’s Pivot
May 18, 2026
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
6 min read
This Week’s CGT News: CRISPR Hits Phase 3 Milestone
May 4, 2026
Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal
6 min read
